Zhejiang Tianyu Pharmaceutical (SHE:300702) expects attributable profit to surge 144% to 238% to between 130 million yuan and 150 million yuan in the first half from 53.2 million yuan in the year-ago period, according to a Monday filing with the Hong Kong bourse.
The drug company's upbeat forecast is attributable to improvements in its gross profit and lower foreign exchange derivative transactions, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments